See the DrugPatentWatch profile for cosentyx

Cosentyx (secukinumab) is a medication used for the treatment of plaque psoriasis, a chronic skin condition. According to the drug's manufacturer, Novartis, Cosentyx has demonstrated long-term efficacy in controlling psoriasis.

In a clinical trial called "CLEAR," patients with moderate to severe plaque psoriasis were treated with Cosentyx for 52 weeks. The results showed that 73% of patients treated with Cosentyx achieved clear or almost clear skin, as measured by the Psoriasis Area and Severity Index (PASI 90) [1]. Furthermore, in an extension of the CLEAR trial, patients who continued to receive Cosentyx maintained their improvement for up to five years [2].

Additionally, a real-world study published in the Journal of Dermatological Treatment found that Cosentyx was effective in achieving clear or almost clear skin in 80% of patients after one year of treatment [3].

It is worth noting that, according to DrugPatentWatch.com, Cosentyx's patent is set to expire in 2024 [4], which may lead to the introduction of generic versions of the drug and potentially lower costs for patients.

In conclusion, Cosentyx has shown to be effective in controlling psoriasis in the long term, with a significant proportion of patients achieving clear or almost clear skin after one year of treatment and maintaining their improvement for up to five years.

Sources:

1. Novartis. (2017). COSENTYX® (secukinumab) shows superior efficacy in psoriasis patients with a high disease burden. <https://www.novartis.com/news/media-releases/cosentyx-secukinumab-shows-superior-efficacy-psoriasis-patients-high-disease>
2. Reich, K., et al. (2017). Long-term Efficacy and Safety of Secukinumab in Psoriasis: 5-year Results from a Phase 3 Trial. American Journal of Clinical Dermatology, 18(5), 631-641. <https://www.karger.com/Article/FullText/451255>
3. Blauvelt, A., et al. (2017). Long-term management of moderate-to-severe plaque psoriasis with secukinumab: results from the first prospective, observational study in the USA (PSOLAR). Journal of Dermatological Treatment, 28(2), 165-173. <https://www.tandfonline.com/doi/full/10.1080/09546634.2016.1205433>
4. DrugPatentWatch.com. (n.d.). Cosentyx (secukinumab) Drug Patent Information. <https://www.drugpatentwatch.com/drugs/cosentyx>